Macro Finance
Sellas Life Sciences Stock Triples After Cancer Vaccine Data
Bloomberg Markets·November 17, 2026·1 min read
Sellas Life Sciences Group Inc. stock tripled after the drug developer reported positive late-stage trial results for an experimental cancer vaccine targeting an aggressive form of blood cancer. The data boosted investor confidence, driving a massive surge in the company's share price.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.